Pfizer starts Lipitor Phase II trial in AD

PFE began a U.S. placebo-controlled Phase II trial of its Lipitor atorvastatin HMG-CoA reductase inhibitor in patients with mild to moderate Alzheimer's Disease (AD). Results of the trial, which is pa...